Enzolytics, Inc. (OTCMKTS:ENZC – Get Free Report) was the target of a significant increase in short interest during the month of May. As of May 15th, there was short interest totaling 972 shares, an increase of 365.1% from the April 30th total of 209 shares. Based on an average daily volume of 45,094,851 shares, the days-to-cover ratio is currently 0.0 days.
Enzolytics Stock Performance
Enzolytics stock opened at $0.00 on Friday. Enzolytics has a fifty-two week low of $0.00 and a fifty-two week high of $0.00.
About Enzolytics
Enzolytics, Inc is a clinical-stage biotechnology company focused on advancing immunotherapeutic treatments for infectious diseases. Its core platform employs proprietary peptide and monoclonal antibody technologies designed to target and neutralize viral pathogens. The company’s lead candidate, Investigator Therapeutic Vaccine-1 (ITV-1), is a 72-amino-acid peptide engineered to bind multiple HIV-1 strains and support immune response in affected individuals.
In addition to its HIV program, Enzolytics has leveraged its antibody discovery engine to develop broadly neutralizing monoclonal antibodies against coronaviruses, including SARS-CoV-2.
Featured Articles
- Five stocks we like better than Enzolytics
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Enzolytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzolytics and related companies with MarketBeat.com's FREE daily email newsletter.
